Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma - a Single Center Phase II Trial

NCT05868395 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT05868395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05868395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma - a Single Center Phase II Trial
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Recruiting
Start date
January 2, 2024
Completion date
May 24, 2027
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle-cell lymphoma